Arman Taghizadeh
Psychiatry · Baltimore, MDNPI 1760528301
Payments from drug & device makers
Across 261 payments — averaging $20.97 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Neos Therapeutics, LP$3K
- Takeda Pharmaceuticals U.S.A., Inc.$1K
- Tris Pharma Inc$453
- AbbVie$337
- Vertical Pharmaceuticals, LLC$146
- Alkermes, Inc.$128
- plus $628 from 11 others
What the payments were for
- Food & beverage$5,473100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Neos Therapeutics, LP | 121 | $2,580 |
| Takeda Pharmaceuticals U.S.A., Inc. | 50 | $1,201 |
| Tris Pharma Inc | 25 | $453 |
| AbbVie(2 entities) | 23 | $337 |
| Vertical Pharmaceuticals, LLC | 9 | $146 |
| Alkermes, Inc. | 1 | $128 |
| Bausch Health US, LLC | 4 | $100 |
| Shire North American Group Inc | 5 | $89 |
| Supernus Pharmaceuticals, Inc. | 4 | $75 |
| Luye Pharma (USA) Ltd. | 4 | $72 |
| Johnson & Johnson | 2 | $51 |
| Ironshore Pharmaceuticals Inc. | 2 | $48 |
| Arbor Pharmaceuticals, Inc. | 3 | $45 |
| Adlon Therapeutics L.p. | 3 | $45 |
| Lundbeck LLC | 2 | $39 |
| Avion Pharmaceuticals | 2 | $33 |
| Vanda Pharmaceuticals Inc. | 1 | $32 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- ARISTADA$514
- LYBALVI$128
- Adzenys XR-ODT$118
- Cotempla XR-ODT$118
How this compares
$5,473 in reported general payments places this provider in the 90th percentile of 851 psychiatry providers in Maryland.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| VyvanseLisdexamfetamine Dimesylate | 12 | $4,202 |
| Vilazodone Hcl | 17 | $1,184 |
| Guanfacine Hcl ErGuanfacine Hcl | 12 | $360 |
| Bupropion XlBupropion Hcl | 16 | $284 |
| Sertraline Hcl | 26 | $45 |
| Clonazepam | 12 | $45 |
| Trazodone Hcl | 12 | $30 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Takeda Pharmaceuticals U.S.A., Inc.Vyvanse | $1,201 | $4,20212 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 851 psychiatry providers in Maryland.
Other psychiatry in Baltimore
- Akira SawaBaltimore$5.1M
- John VaethBaltimore$2.1M
- Paul RosenbergBaltimore$1.9M
- Scott AaronsonBaltimore$1.3M
- Karen AndersonBaltimore$1.1M
- Constantine LyketsosBaltimore$1.1M
- Alan JonasBaltimore$1.1M
- Sarah HertsBaltimore$1M
- Robert LehmanBaltimore$947K
- Marc FishmanBaltimore$822K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.